PBM Rose 24.2% After Backing Action to Speed Ibogaine

Psyence BioMed (Nasdaq: PBM) rose 24.2% on Aug 18, 2026 after the company welcomed the U.S. administration’s latest action aimed at accelerating ibogaine development.

What Psyence BioMed announced

Psyence BioMed said it welcomed President Donald J. Trump’s latest announcement supporting the accelerated development of ibogaine as a potential medical treatment in the United States. The company describes itself as a biopharmaceutical business focused on developing and supplying nature-derived psychedelic compounds for clinical research and therapeutic applications. In plain English: PBM is aligning itself with a policy tailwind it believes could speed up the path for ibogaine-related work in the U.S.

What it means for Psyence BioMed

For a company tied to psychedelic compounds, public support from the top of the U.S. government can matter because it may shape the pace and priority of research and development efforts. PBM’s statement positions it to benefit if “accelerated development” translates into clearer pathways for clinical research and therapeutic use. The announcement itself doesn’t lay out new trial results or a new product launch, but it signals that the company sees momentum building around ibogaine as a potential treatment. More broadly, it underscores how much of PBM’s story is linked to regulatory and policy direction, not just lab work.

How the stock reacted

PBM traded lower early, then finished sharply higher by the close.

Window	Move
5 min	-0.1%
10 min	-0.3%
30 min	-0.4%
1 hour	-1.1%
end of day	+24.2%

On a market-adjusted basis, PBM’s move was +24.3% versus the SPY on the day.